Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06891898 · ClinicalTrials.gov registry record
The iLet Experience Study
A clinical trial of Type 1 Diabetes, sponsored by Beta Bionics.
- Recruiting
- Registry status
- 1,875
- Enrollment target
- 1
- Study location
NCT06891898: Recruiting study of Type 1 Diabetes, sponsored by Beta Bionics.
NCT06891898 is a study of Type 1 Diabetes that is actively recruiting participants, run by Beta Bionics. The registered enrollment target is 1,875 participants, above the 757-participant average among 198 other Type 1 Diabetes trials with a reported enrollment target (148% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06891898, a study of Type 1 Diabetes, is actively recruiting participants, sponsored by Beta Bionics.
- RECRUITING
- Registry status
- 1,875 participants
- Enrollment target
- 1
- Study location
Study Summary
A one-year, prospective single-arm cohort study to collect safety and effectiveness data on the iLet Dosing Decision Software during real-world use in people 6 years of age or older with type 1 diabetes (T1D) with 12 months follow-up.
Primary Outcome
Number of severe hypoglycemia events associated with cognitive impairment requiring the assistance of a third party for treatment per 100 patient years
Conditions Studied
Interventions
- DEVICE iLet Dosing Decision Software
Study Locations (1)
California
- Beta Bionics - Irvine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,875 participants |
| Start Date | 2024-05-01 |
| Est. Completion | 2027-06 |
What NCT06891898 shows while recruiting
NCT06891898 is an observational study that tracks outcomes without assigning an intervention. Its 1,875 participants enrollment target places it among the larger protocols in the corpus, above the 757-participant average among 198 other Type 1 Diabetes trials with a reported enrollment target (148% higher).
The record links to 1 condition, with Type 1 Diabetes appearing as the primary indexed condition, and to 1 intervention - of which iLet Dosing Decision Software is the first listed.
NCT06891898 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06891898 about?
NCT06891898 is a clinical study titled "The iLet Experience Study". A one-year, prospective single-arm cohort study to collect safety and effectiveness data on the iLet Dosing Decision Software during real-world use in people 6 years of age or older with type 1 diabetes (T1D) with 12 months follow-up.
What is the current status of trial NCT06891898?
This trial is currently recruiting. The enrollment target is 1,875 participants. The study started on 2024-05-01. Estimated completion is 2027-06.
What conditions does trial NCT06891898 study?
This clinical trial studies the following conditions: Type 1 Diabetes.
What interventions are being tested in trial NCT06891898?
The interventions under investigation include: iLet Dosing Decision Software (DEVICE).
Who is sponsoring clinical trial NCT06891898?
This trial is sponsored by Beta Bionics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06891898 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 1 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06891898's enrollment target sits among peer trials
1,875 8th of 198 higher than 191 of 198 other Type 1 Diabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 1 Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
MANATEE-T1D: Metformin ANd AutomaTEd Insulin Delivery System Effects on Renal Vascular Resistance, Insulin Sensitivity, and Cardiometabolic Function in Youth With Type 1 Diabetes
RECRUITING · Phase 1
-
Multivariable Artificial Pancreas: Detecting and Mitigating Unannounced Physical Activity and Acute Psychological Stress
RECRUITING
-
Extended Bolus for Meals in a Closed-loop System
RECRUITING · Phase 4
-
REAL-Fam Feasibility Study for Youth Diabetes Management
RECRUITING · NA
-
A Study to Investigate Safety and Effectiveness of Porcine Pancreatic Cells (OPF-310) in Patients With Type 1 Diabetes Mellitus
RECRUITING · Phase 1
-
AIDANET Pediatrics
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05675410 · 1,875 participants · Phase 3
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
- NCT07356089 · 1,875 participants
Twiist Postmarket Surveillance Study for Type 1 Diabetes
- NCT07203313 · 1,872 participants · NA
Evaluation of Aim to Play, a User-Friendly Digital Application for Teacher Skills Training and Physical Education Activities for 3-5 Grade Students
- NCT06438640 · 1,881 participants · NA
Evaluating a Strategy to Improve Pre-Anesthesia Care Discussions (My Anesthesia Choice-Hip Fracture)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI